Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach

View ORCID ProfileRiffat Mehboob, View ORCID ProfileFridoon Jawad Ahmad, Ahad Qayyum, Muhammad Asim Rana, View ORCID ProfileSyed Amir Gilani, Muhammad Akram Tariq, View ORCID ProfileJaved Akram
doi: https://doi.org/10.1101/2020.08.01.20166678
Riffat Mehboob
1Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Riffat Mehboob
  • For correspondence: mehboob.riffat@gmail.com
Fridoon Jawad Ahmad
2Deparmtnet of Physiology, University of Health Sciences, Lahore, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fridoon Jawad Ahmad
Ahad Qayyum
3Bahria International Hospital, Lahore, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Muhammad Asim Rana
3Bahria International Hospital, Lahore, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Syed Amir Gilani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Syed Amir Gilani
Muhammad Akram Tariq
4Higher Education Department Punjab, Lahore, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javed Akram
2Deparmtnet of Physiology, University of Health Sciences, Lahore, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Javed Akram
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Corona virus infection is a respiratory infection, compromising the normal breathing in critical patients by damaging the lungs. Researches are ongoing to find an efficient treatment strategy for this disease by either inactivating the virus or boosting the immune system of patient or by managing the cytokine storm.

Aim To evaluate the clinical outcomes of Substance P receptor Neurokinin 1 antagonist in Covid-19 patients against the usual treatments as controls.

Patients and Methods It is a randomized clinical trial, open label, having two arms, one receiving normal management and care while other receiving Neurokinin-1 Receptor antagonist, Aprepitant, in addition. Dexamethasone, a corticosteroid is also administered orally to both the groups. PCR positive, hospitalized patients with more than 18 years of age, both genders, moderate to critical phase were included. 18 patients were randomly allocated in both arms, having 10 in group A and 8 in group B. Lab investigations were performed in both the groups before and after the intervention. We report preliminary results for the comparison of Aprepitant 80 mg given once daily for 3-5 days vs routine management. The primary outcome was total in hospital days and duration of disease.

Results Mean age of patients in group A was 47.63 ±12.07years while 60.90± 9.75 years in group B. There were 3/8 males in group A and 8/10 in group B. There were 2 critical patients in group A and 5 in group B. Biochemical and hematological parameters in both groups didn’t show much difference except the C-reactive protein reduction in the intervention group, indicative of a reduced inflammation. Oxygen saturation also improved but more patients should be enrolled to get a statistically significant data. One patient was discharged from each group within 5 days and one patient expired in each.

Conclusions It is a pilot study but the findings give a strong clue for the therapeutic potential of Aprepitant. Patients who received a combination therapy of Aprepitant and Dexamethasone were recovered earlier and showed improved clinical outcomes, laboratory findings and reduced C-reactive protein which is an inflammatory marker. We suggest here a study on larger sample size to get a deeper insight of its potential and efficacy. It may be more effective in severe to critical patients having respiratory difficulties.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04468646

Funding Statement

No funding was received

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB approval was obtained from Bahria International Hospital where the study was performed

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of Interest Authors declare no conflict of interest

  • One author Syed Amir Gilani is added

Data Availability

Data will be made available on request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 05, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach
Riffat Mehboob, Fridoon Jawad Ahmad, Ahad Qayyum, Muhammad Asim Rana, Syed Amir Gilani, Muhammad Akram Tariq, Javed Akram
medRxiv 2020.08.01.20166678; doi: https://doi.org/10.1101/2020.08.01.20166678
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Aprepitant as a combinant with Dexamethasone reduces the inflammation via Neurokinin 1 Receptor Antagonism in severe to critical Covid-19 patients and potentiates respiratory recovery: A novel therapeutic approach
Riffat Mehboob, Fridoon Jawad Ahmad, Ahad Qayyum, Muhammad Asim Rana, Syed Amir Gilani, Muhammad Akram Tariq, Javed Akram
medRxiv 2020.08.01.20166678; doi: https://doi.org/10.1101/2020.08.01.20166678

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (51)
  • Cardiovascular Medicine (455)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (159)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5297)
  • Forensic Medicine (3)
  • Gastroenterology (198)
  • Genetic and Genomic Medicine (760)
  • Geriatric Medicine (80)
  • Health Economics (214)
  • Health Informatics (702)
  • Health Policy (363)
  • Health Systems and Quality Improvement (224)
  • Hematology (100)
  • HIV/AIDS (165)
  • Infectious Diseases (except HIV/AIDS) (5938)
  • Intensive Care and Critical Care Medicine (368)
  • Medical Education (105)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (772)
  • Nursing (43)
  • Nutrition (135)
  • Obstetrics and Gynecology (146)
  • Occupational and Environmental Health (234)
  • Oncology (481)
  • Ophthalmology (153)
  • Orthopedics (39)
  • Otolaryngology (97)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (138)
  • Primary Care Research (99)
  • Psychiatry and Clinical Psychology (865)
  • Public and Global Health (2035)
  • Radiology and Imaging (354)
  • Rehabilitation Medicine and Physical Therapy (159)
  • Respiratory Medicine (287)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)